HLA-C and cancer: It comprehensively characterizes all molecular features involved in different types of cancer immunotherapy, from the original gene sequence information, to the pathogenic variant characteristics, genes, peptide sequences, protein sequences, and the corresponding disease types, the status of corresponding therapies, including whether they are approved for use or in clinical trials, the manufacturer, and the study status and phase of the clinical trials, etc. In addition, DIRMC provides a prediction interface that allows users to predict the interaction of peptides of interest with MHC or TCR.